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INTRODUCTION: Tamoxifen reduces breast cancer risk, but can cause thromboembolic complications.
Cerebral venous thrombosis is a rare form of stroke in which blood clots occlude the dural sinus or
cerebral veins.
PRESENTATION OF CASE: A 46-year old female presented with a severe headache and nausea of subacute
onset. She had undergone masectomy for breast cancer 20 months ago and had been taking tamox-
ifen. Brain CT and MRI conﬁrmed cerebral venous infarction and venous thrombosis in the superior
sagittal sinus and straight sinus. She had elevated D-dimer level, decreased levels of protein S activ-
ity and antithrombin III. Doppler ultrasound revealed concurrent deep vein thrombosis in her right leg.
There was no evidence of breast cancer recurrence. With oral anticoagulation, she discharged without
neurological complications. The abnormal laboratory ﬁndings of coagulopathy returned to normal after
discontinuation of tamoxifen.
DISCUSSION: Considering the abnormal ﬁndings in the workup of coagulopathy and no other risk factor
for venous thrombosis, this thromboembolic complication can be attributed to the coagulopathy with
use of tamoxifen.
CONCLUSION:Clinicians shouldwarn about the possibility of thromboembolic complicationswith tamox-
ifen.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Tamoxifen is a selective estrogen receptor modulator, which
is used for both breast cancer treatment and prevention. How-
ever, tamoxifen could induce an acquired hypercoagulable state
by reducing the levels of natural anticoagulant proteins.1,2 Despite
the clinical beneﬁt of tamoxifen therapy on breast cancer, there
was an increased risk of thromboembolic complications includ-
ing ischemic stroke.3–6 Cerebral venous thrombosis (CVT) is a
rather uncommon form of stroke, in which thrombosis of the dural
sinus or cerebral veins leads to infarction, hemorrhage, or both.
It arises in close association with hypercoagulable states, puer-
perium, oral contraceptives, and malignancy. We present a case
of a breast cancer patient who developed CVT and concurrent deep
vein thrombosis (DVT)with the use of tamoxifen, probably through
a hypercoagulable state.
Abbreviations: CVT, cerebral venous thrombosis; DVT, deep vein thrombosis.
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2. Case report
A 46-year old female was admitted for severe headache and
vomiting that started two weeks ago. The patient was alert, fully
oriented, and did not have fever or demonstrated any signs of
infection. Shedidnot have ahistory ofmigraine anddenied thepos-
sibility of pregnancy or use of oral contraceptive. Twenty months
ago, this patient had been diagnosed with breast cancer for which
she underwent breast conserving surgerywith axillary lymphnode
dissection. As she was found to have estrogen-receptor positive
invasive ductal carcinoma without metastasis, to prevent recur-
rence of breast cancer, she had been taking tamoxifen 200mgdaily.
During the follow-upperiod, therewasnoevidenceof breast cancer
recurrence; the whole-body positron emission tomography scan
taken two months ago did not show evidence of local or distant
recurrence.
Upon admission, a non-contrast CT scan revealed a poorly
demarcated space-occupying lesion with hypointense signal in the
left basal ganglia and thalamus (Fig. 1A). Under the impression of
brain metastasis or primary tumor with peritumoral edema, brain
MRI scan was performed. T2-weighted brain MRI revealed a het-
erogeneous signal intensity involving the left basal ganglia, and
thalamus (Fig. 1B). Sagittal T1-weighted imaging showed a throm-
bus occluding the superior sagittal sinus and straight sinus (Fig. 1C
http://dx.doi.org/10.1016/j.ijscr.2014.11.068
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Fig. 1. Cerebral venous infarction in left periventricular area. (A) Non-contrast brain CT. (B) T2-weighted MRI. (C) Sagittal T1-weighted MRI shows sinus thrombosis (arrow).
(D) Gradient-echo MRI.
arrow), and gradient-echo imaging revealed hemorrhagic change
of the lesion (Fig. 1D). Based on the MRI, she was diagnosed as CVT
with edematous changes that occurred from thrombosis of cere-
bral sinus. Even though she did not complain of pain or weakness
of leg, her right leg was disproportionately large by inspection and
she reported slight tenderness upon palpation. Under the impres-
sion of concurrent DVT, she underwent Doppler ultrasound, which
conﬁrmed partial obstruction with internal thrombus at the con-
ﬂuent level of posterior tibial vein, just distal to trifurcation of right
popliteal vein (Fig. 2, arrow).
We performed tests for clotting abnormalities before anticoag-
ulant therapy. Protein C activitywaswithin the normal rangewhile
protein S activity was decreased to 47% (normal range of 55–123)
and antithrombin III to 73% (normal range of 83–128). Lupus anti-
coagulant and anticardiolipin antibodies were not detected. Factor
V Leiden gene mutation, which is associated with protein S deﬁ-
ciency, was negative. Homocysteine was within the normal range.
Both D-dimer and ﬁbrinogenwere elevated to 2796.90ng/mL (nor-
mal range of 0–500) and 477mg/dL (normal range of 231–473),
respectively.
After the diagnosis of CVT, she was treated with an oral anti-
coagulant. Because she was obese with the body mass index
of 29.5 kg/m2, we encouraged her to exercise regularly and
stressed the importance of reaching her ideal body weight. With
the prothrombin time kept within the therapeutic range (2–3
by international normalized ratio), she was discharged home
headache-free and without focal neurologic signs. For preven-
tion of breast cancer, tamoxifen is substituted with anastrozole
which is another inhibitor of aromatase and without thrombotic
complication.5 After one month of oral anticoagulation, follow-up
MRI revealed resolution of the space-occupying lesion and cerebral
venous thrombus (Fig. 3). After six months from discontinuation of
tamoxifen, the laboratory abnormalities of coagulation returned to
normal (protein S, antithrombin III, D-dimer, and ﬁbrinogen).
3. Discussion
Tamoxifen, through its tissue-speciﬁc antagonist effects on
estrogen receptors inmammary tissue, has been shown to decrease
mortality and recurrence in all stages of breast cancer and to reduce
the incidence of breast cancer in high-risk women.5,6 Despite such
beneﬁts rendered by the agent, there has been heightened concern
that tamoxifen use increases the risk of thrombotic complications.3
One meta-analysis showed that those treated with tamoxifen had
an 82% increased risk of ischemic stroke.7 In randomized trials, the
association between the risk of thromboembolic events and the
use of tamoxifen was also signiﬁcant.4,8 The ﬁrst two years after
the initiation of tamoxifen therapy, which was also the case for our
patient, was considered to be the most vulnerable time to devel-
oping venous thromboembolic complications9 After diagnosis of
CVT, the case patient took anastrozole in place of tamoxifen. The
anastrozole is a new aromatase inbibitor and known to have fewer
thromboembolic complications.5
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Fig. 2. Doppler ultrasonography of right popliteal vein. There is partial obstruction of the posterior tibial vein (blue color) by the thrombus as indicated by the arrows. (A)
Transverse image. (B) Axial image.
Fig. 3. Follow-up brain MRI after one month. The lesion of left basal ganglia and sinus thrombus were disappeared. (A) Axial T2-weighted MRI. (B) Sagittal T1-weighted MRI.
Even though themechanisms bywhich tamoxifen increases the
risk of thrombosis have yet to be elucidated, alterations in the con-
centrations of natural anticoagulants have been implicated.1 Like
in this case, a signiﬁcant decrease in both protein S activity and
antithrombin III level were reported in tamoxifen users.2
This patient had a history of breast cancer, and cancer itself
is another predisposing condition for thrombotic complications.
However, there was no evidence of cancer recurrence during the
follow-up period. Therefore, we concluded that tamoxifen-related
hypercoagulabilitywas themain causeof venous thrombosis rather
than the breast cancer itself. The concurrent DVT and normaliza-
tion of coagulopathy after discontinuation of tamoxifen likewise
attests to the presence of underlying hypercoagulable condition
with tamoxifen.
4. Conclusion
This case illustrates concurrent CVT and DVT suspected to have
arisen from the use of tamoxifen. Clinicians should warn about
the possibility of thromboembolic complications with tamoxifen.
Especially for those with an elevated risk of thromboembolism, a
physician may need to consider new aromatase inhibitors without
thromboembolic risk.
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